 Pyrimidines
"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 4 | 0 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 4 | 0 | 4 | | 2005 | 3 | 1 | 4 | | 2006 | 6 | 5 | 11 | | 2007 | 4 | 2 | 6 | | 2008 | 8 | 6 | 14 | | 2009 | 8 | 4 | 12 | | 2010 | 10 | 2 | 12 | | 2011 | 8 | 4 | 12 | | 2012 | 7 | 12 | 19 | | 2013 | 6 | 10 | 16 | | 2014 | 7 | 8 | 15 | | 2015 | 11 | 10 | 21 | | 2016 | 7 | 7 | 14 | | 2017 | 7 | 9 | 16 | | 2018 | 12 | 4 | 16 | | 2019 | 10 | 11 | 21 | | 2020 | 5 | 9 | 14 | | 2021 | 10 | 11 | 21 | | 2022 | 2 | 12 | 14 | | 2023 | 2 | 3 | 5 | | 2024 | 7 | 10 | 17 | | 2025 | 6 | 10 | 16 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134.
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
-
Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F. Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial. Eur J Heart Fail. 2025 Dec; 27(12):2825-2836.
-
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025 Sep 27; 406(10510):1351-1362.
-
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025 Sep 27; 406(10510):1341-1350.
-
Zannad F, Reddy YNV, Barash I, Anstrom KJ, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor CM, Ponikowski P, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Butler J. Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. J Am Coll Cardiol. 2025 Dec 16; 86(24):2471-2491.
-
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Talpaz M, Gerds AT, Lyons R, Langmuir P, Hunter D, Lamothe B, Hou K, McMahon B. A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leuk Res. 2025 Aug; 155:107732.
-
Assouline SE, Mehta A, Hanel W, Doucet S, Johnston PB, Danilov A, Cooper BW, Chudnovsky A, Ding J, Long T, Stroopinsky D, Berg D, Alinari L. Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Nov; 25(11):788-799.e11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|